How to choose AAV resins? This article explains the differences and selection of AAV affinity resins, AAV chromatography resins, and AAV purification resins

Opening: From the Gene Therapy Boom to the Hidden Key Battleground in "Bottles and Jars"

If you've been following the biopharma news over the past couple of years, you must be familiar with terms like "gene therapy" and "one-time cures for rare diseases." And in the billion-dollar gene therapy arena, adeno-associated virus (AAV) vectors are undoubtedly the brightest stars right now—ranging from Zolgensma for treating spinal muscular atrophy to hundreds of ongoing AAV gene therapy clinical trials worldwide, AAV is turning the sci-fi scenario of "one dose for long-term effect" into reality.

But what you might not know is that every AAV drug that enters a patient goes through an extremely rigorous "purification test" before leaving the factory. While upstream AAV production (cell culture, virus amplification) is important, the real factors that determine cost, purity, and safety lie in the downstream purification step—this step accounts for 50%–70% of total production costs. Among these, the most critical, expensive, and technically challenging materials are AAV resins.

So, what exactly is an AAV resin? What's the difference between AAV affinity resins, AAV chromatography resins, and AAV purification resins, which all seem similar? As a process developer, when staring at a dizzying array of product manuals, how do you make the right choice? Today, this article will clarify these keywords for you, helping you avoid detours and pitfalls.

1. Understanding the Relationship Among Four Concepts: Who Includes Whom?

Let's start with the conclusion: these four terms aren't on the same level—they have a nested relationship.

From largest to smallest: AAV purification resins > AAV chromatography resins > AAV affinity resins ≈ the commonly referred-to "AAV resin."

Specifically:

AAV purification resins: The broadest concept, referring to all resins used in AAV purification processes, including affinity resins, ion-exchange resins, hydrophobic resins, size-exclusion resins, tangential flow membranes, etc. Any material used for AAV purification qualifies.

AAV chromatography resins: Resins used in AAV purification based on chromatography principles; they are the core and most commonly used type within "AAV purification resins." Mainly includes affinity chromatography resins, ion-exchange chromatography resins, hydrophobic chromatography resins, mixed-mode chromatography resins, etc.

AAV affinity resins: Resins that capture AAV through specific affinity ligands; they have the highest technical barriers, strongest selectivity, and best single-step purification effects among AAV chromatography resins. They are currently considered the "gold standard" capture media for downstream AAV purification.

AAV resins: A shorthand used in daily industry conversation, usually referring to AAV affinity resins but sometimes broadly referring to various AAV purification resins. The exact meaning depends on context.

In short: purification is the largest category, chromatography is the main workhorse, affinity is the core, and "AAV resin" commonly refers to affinity resins.

AAV resin

2. AAV Affinity Resins: Why Are They the "Star Product" in AAV Purification?

Among all AAV resins, affinity resins for AAV definitely get the most attention and have the highest technical content—period.

The reason is simple—purifying AAV virus particles is really tough. In traditional antibody processes, Protein A as a universal capture ligand is highly mature, but AAV doesn’t have a similar 'one-size-fits-all' ligand. Different serotypes have large differences in capsid surface sequences and charges, and separating empty capsids, full capsids, and aggregates is difficult. This makes AAV chromatography more dependent on serotype-specific screening and multi-step orthogonal purification than antibodies. AAV also has low titers, complex host protein and DNA impurities, and the surface charge and hydrophobicity vary significantly between serotypes. Using conventional ion exchange or hydrophobic resins often results in low yield and substandard purity.

The emergence of AAV affinity resins has directly boosted AAV purification efficiency by an order of magnitude. Their principle is similar to Protein A in antibody purification: an affinity ligand that specifically binds AAV particles is immobilized onto a chromatographic matrix, usually an affinity peptide, single-domain antibody, or antibody fragment targeting the AAV capsid protein. When cell culture supernatant or cell lysate containing AAV passes through the column, AAV particles are specifically 'captured' by the ligand while most impurities flow through, and then AAV is eluted under suitable conditions, achieving high purity in a single step.

Currently, mainstream AAV affinity resins follow a few technical routes: one is based on heavy-chain single-domain antibodies (VHH, ~12 kDa) from camelid animals, produced via recombinant yeast expression. This was among the first commercially available AAV affinity resins and is suitable for multiple serotypes, still preferred for many labs and early clinical production. The second route uses similar single-domain antibody technology to create highly selective products with high selectivity, fast flow rates, and good pressure tolerance, with some versions achieving recovery over 80%, making them especially suitable for industrial production. The third approach uses affinity peptides, with some products offering cost advantages and alkali resistance. The fourth is the recent rise of domestic AAV affinity resins, breaking new ground in binding capacity, alkali resistance, and serotype coverage, offering clear cost-effectiveness.

The core value of AAV affinity resins is that they can capture high-purity AAV samples in a single step. With appropriate ligand-serotype matching and optimized processes, mature capture step recovery is usually 50%–80%, but for new serotypes or unoptimized processes it can drop below 30%, with significant differences between products. They greatly simplify the purification process, shorten process development timelines, and are especially useful for quickly obtaining high-purity AAV samples in early research and clinical production.

3. AAV Chromatography Resins: More Than Just Affinity, Plus These Key Roles

Although AAV affinity resins are the highlight, a complete AAV purification process definitely can’t rely on just one affinity column. AAV chromatography resins form a big family, where different types of resins each have their role, working together to get from crude extract to high purity.

In a typical AAV purification process, commonly used AAV chromatography resins include these categories:

The first type is affinity chromatography resins, the AAV affinity resins mentioned earlier, which are responsible for capturing AAV from cell lysates or supernatants in one step, achieving rapid enrichment and initial purification. This is the most valuable member of the AAV resin family.

The second type is ion exchange chromatography resins, including cation and anion exchange resins, mainly used for polishing steps after affinity capture. They remove residual host proteins, DNA, endotoxins, as well as product-related impurities like empty capsids and aggregates, and can also be used for separating and enriching empty/full capsids. The principle relies on the slight differences in surface charge between empty and full AAV particles—the full particles wrap negatively charged single-stranded DNA genomes, giving their capsids a higher net negative charge than empty capsids, and the apparent isoelectric point is usually lower than that of empty capsids (exact values vary with serotype and measurement methods; common empty capsid pI is about 0.2–0.5 pH units higher than full capsids). This is the physical basis for AEX separation of empty/full capsids, and fine control of pH and salt concentration can achieve their separation. Different AAV serotypes have different isoelectric points, so the choice of ion exchange resins and process conditions also varies.

The third type is hydrophobic interaction chromatography resins, which separate based on differences in surface hydrophobicity of AAV particles. They are often used to remove AAV aggregates and some impurities. For certain serotypes, hydrophobic chromatography can also help partially separate empty and full capsids.

The fourth type is mixed-mode chromatography resins, combining multiple mechanisms such as ion exchange and hydrophobicity. They have more unique selectivity and can handle impurities that conventional resins struggle with, making them increasingly important for polishing complex AAV samples.

The fifth type is size-exclusion chromatography (SEC) resins, also called gel filtration resins, which separate based on molecular size. They’re commonly used in the final polishing step to remove aggregates and trace impurities while exchanging buffers. But they have relatively low capacity, so they’re usually used at the very end of the process.

It’s clear that AAV affinity resins are the “main force” among AAV chromatography resins, but to produce AAV products that meet clinical and commercial standards, combining and optimizing multiple resins is essential.

4. AAV Purification Resins: A Complete Material System from Crude Extract to Finished Purity

AAV-purification resin

If AAV chromatography resins are the 'main force' in AAV purification, then AAV purification materials are more like the 'entire army'—they include not only chromatography resins but also all functional fillers and media used in every step of AAV purification.

Besides the various chromatography resins mentioned above, AAV purification materials may also include:

4.1. Tangential flow filtration (TFF) cassettes or membrane columns, used for cell harvest, concentration, and buffer exchange. Strictly speaking, these are membranes, not 'resins,' but they are indispensable upstream unit operations in AAV purification processes.

4.2. Clarification filtration media, used for clarifying cell lysates or culture supernatants to remove cell debris and large particulate impurities.

4.3. Immobilized nuclease resins, used in some processes to remove residual host DNA. More commonly, soluble, broad-spectrum nucleases are added directly.

4.4. Sterile filtration membranes, used for final product sterile filtration.

Of course, in everyday industry conversations, when people talk about AAV purification materials, they usually mean the chromatography resin combinations centered around affinity resins. But as a process developer, you need to have a full 'purification material checklist' in mind—you can't just focus on affinity columns.

Turning point: what to do when off-the-shelf resins 'fail'?

After talking about these 'off-the-shelf' AAV purification materials, you might think: isn't selecting them just a matter of buying according to the serotype comparison table? But reality is far more complicated than the manual. When you encounter a rare natural serotype or a newly engineered chimeric capsid, you'll find that mainstream AAV affinity resins either have their binding capacity halved or simply 'refuse to bind'; or perhaps your process requirements are very demanding, and you want to increase the cleaning alkali concentration from 0.1M to 0.5M to extend resin life and reduce production costs, but the existing ligands deactivate and fail in high alkali conditions. Even worse, some special serotypes have no commercial AAV chromatography resins available at all—you can’t buy them even if you want to.

Facing these 'no resin available' tough cases, the traditional approach is a lengthy, multi-year, massive random mutation screening—it’s not only long but has an extremely low success rate. Nowadays, AI-driven protein directed evolution technology is providing a whole new solution—using machine learning to accurately predict functional sites of ligands, directing the optimization of key properties like affinity, alkali tolerance, and specificity, turning a 'needle in a haystack' into 'precision-guided.' This is where the MatwingsVenus™ (Xiaowu™) intelligent platform comes into play.

5. MatwingsVenus™ (Xiao Wu™) Agent: AI-Powered AAV Resin Performance Upgrade and Process Development Acceleration

In the entire chain from AAV ligand development to process application, the MatwingsVenus™ (Xiao Wu™) agent leverages AI-driven protein design technology at its core. It provides full-chain intelligent support for optimizing AAV affinity ligands, selecting and combining AAV chromatography resins, and overall process development of AAV purification resins. By relying on a self-developed protein large model and a closed-loop wet and dry experiment system, MatwingsVenus™ (Xiao Wu™) can accurately predict high-affinity, highly specific ligand sequences tailored to the structural features of capsid proteins of different AAV serotypes and directionally optimize industrial key properties like alkali resistance and elution conditions, compressing the traditional "needle-in-a-haystack" screening cycle from several years to just a few months or even weeks.

MatwingsVenus™ online store

At the product level, MatwingsVenus™ (XiaoWu™) has developed multiple self-researched AAV affinity resin products. Users can access product information and technical consultation through the Matwings Mall, quickly meeting the initial needs of AAV research and process development. At the same time, MatwingsVenus™ (XiaoWu™) provides flexible customization services—targeting specific serotypes or specially modified AAV vectors, the company offers end-to-end services from custom ligand design for AAV affinity resins, resin development, to full AAV purification resin process optimization and scale-up validation, truly achieving the concept of 'you give me the sequence requirement, I return a dedicated resin,' helping gene therapy companies quickly establish efficient, stable, and compliant AAV purification processes.

6. FAQ

Q1: Can AAV affinity resins be used for all serotypes?

Not necessarily. Different AAV affinity resins recognize specific epitopes on the AAV capsid protein, and the capsid protein sequences and structures vary across serotypes, so the binding profiles differ. For example, the earliest commercial AVB Sepharose (Cytiva, llama VHH ligand) binds well to AAV1, 2, 3, 5, 6, and AAVrh10 but hardly binds to AAV4 and AAV9, and has lower recovery for AAV8 (often <50%). Before choosing, you must confirm whether the target serotype falls within the resin's binding profile or perform small-scale experiments to verify.

Q2: Why use other AAV chromatography resins if there’s affinity resin?

Because although affinity resins are highly selective, a single-step purification usually doesn’t meet the purity requirements of clinical-grade AAV. After affinity capture, trace amounts of host proteins, DNA, endotoxins, as well as empty capsids and aggregates may remain, which require further removal using ion exchange, hydrophobic, mixed-mode, and other AAV chromatography resins. Especially for separating empty and full particles, affinity resin alone is usually insufficient, and anion exchange chromatography and other polishing steps are typically needed. A mature AAV purification process generally combines 'affinity capture + 1-2 polishing steps + final purification.'

Q3: Is there a big difference between domestic and imported AAV resins?

In recent years, domestic AAV affinity resins have improved significantly, with some products already matching mainstream imported products in terms of binding capacity, recovery rate, and alkali resistance, while offering clear cost advantages and shorter lead times. The main differences lie in coverage of certain special serotypes, large-scale verification data for long-term stability, and completeness of regulatory support documents. For early research and preclinical stages, domestic resins are already a cost-effective choice; for late-stage clinical and commercial phases, it’s necessary to comprehensively evaluate performance, supply stability, and regulatory support.

Q4: How much of the AAV production cost is typically accounted for by the cost of AAV purification resins?

The downstream purification cost of AAV usually accounts for 50%–70% of the total production cost, and AAV purification resins are a major part of this downstream cost, especially affinity resins—the price per liter often reaches tens of thousands of yuan or even higher. This is also why the industry has been pushing for the development of high-capacity, long-lifespan AAV affinity resins. Every increase in resin capacity and extension of lifespan significantly reduces the cost per unit of production.

Q5: When developing an AAV process, which type of AAV resin should you start with?

It is recommended to start with AAV affinity resins. Begin with the capture step using affinity resins for preliminary optimization. Once you have AAV samples with decent purity, you can then select appropriate ion exchange or other AAV chromatography resins for polishing based on the impurities in your sample. This approach—from core to periphery—is the most efficient. For new serotypes or modified AAVs, it is recommended to first carry out small-scale resin screening experiments, rather than buying large amounts of resin right away.

7. Final Summary

The core logic of AAV purification is actually quite clear: first use AAV affinity resins to capture the bulk, then use various AAV chromatography resins for polishing, combining everything into a complete AAV purification resin scheme—this is the basic routine for AAV resin process development.

With the continuous growth of the gene therapy field, domestic AAV resins, especially AAV affinity resins, are being upgraded more rapidly. The involvement of AI protein design technology is moving AAV affinity ligand development from "trial-and-error screening" to "precise design." The emergence of intelligent platforms like MatwingsVenus™ (XiaoWu™) is also expected to further promote the localization and intelligent upgrading of AAV chromatography resins and complete AAV purification solutions, providing more reliable supply chain support for the downstream purification steps in China's gene therapy industry. This way, purification processes will no longer be a bottleneck in the development of gene therapy drugs.